Is neutrophil-lymphocyte ratio a novel biomarker for macrovascular and microvascular complications of type 2 diabetes?

Walaa H. Mohammad^a, Ahmad B. Ahmad^b, Muhammad H. Al-Maghraby^b, Mohamed Z. Abdelrhman^c, Sanaa Ezzate^d

^aDepartment of Internal Medicine, Nephrology Unit, ^bDepartment of Internal Medicine, Cardiology and Critical Care Unit, ^cDepartment of Clinical Pathology, ^dDepartment of Internal Medicine, Hematology Unit, Assiut University Hospital, Assiut, Egypt

Correspondence to Walaa H. Mohammad, MD, Department of Internal Medicine, Assiut University Hospital, Assiut, 71515, Egypt, Tel: +20 100 522 0944/+20 112 009 6322/+20 882 294 539; e-mails: walaa.hosny2012@gmail.com, walaa. hosny@aun.edu.eg

Received 18 July 2018 Accepted 26 July 2018

The Egyptian Journal of Internal Medicine 2019, 31:1–7

Background/aim

The neutrophil-to-lymphocyte (N/L) ratio is a biomarker of inflammation. We aimed to test the hypothesis that macrovascular and microvascular complications of type 2 diabetes mellitus (DM) involve an inflammatory process.

Patients and methods

This is a cross-sectional study conducted on patients with type 2 DM. Demographic and clinical examination data of eligible patients were recorded. The blood samples for laboratory variables were collected and measured by the standard methods. A standard ultrasound examination was done to measure both carotid artery intimamedia thickness (cIMT), and the averages of three results of each side were recorded.

Results

The current study showed that N/L ratio was an independent predictor of cIMT in patients with type 2 DM (*B*=0.003, *t*=8.325, *P*=0.000), in addition to other conventional cardiovascular risk factors including age, male sex, smoking index, duration of diabetes, estimated glomerular filtration rate, low-density lipoprotein-cholesterol, urinary albumin creatinine ratio, and HBA1c. Moreover, N/L ratio was an independent predictor of albuminuria in patients with type 2 DM (*B*=0.110, *t*=3.638, *P*=0.006), in addition to duration of diabetes, HBA1c, SBP, BMI, and estimated glomerular filtration rate.

Conclusion

N/L ratio was an independent predictor of cIMT and albuminuria. This supports the hypothesis that diabetic macrovascular and microvascular complications involve an inflammatory process. Therefore, NLR may serve as a cost-effective and readily accessible marker of diabetic vascular complications.

Keywords:

diabetic macrovascular and microvascular complications, neutrophil-lymphocyte ratio, novel biomarkers in diabetes

Egypt J Intern Med 31:1–7 © 2019 The Egyptian Journal of Internal Medicine 1110-7782

Introduction


Type 2 diabetes mellitus (DM) has many microvascular and macrovascular complications [1]. Carotid artery intima-media thickness (cIMT) is a well-established biomarker of subclinical atherosclerosis and can be used as a predictor for macrovascular events [2]. Albuminuria is an early indicator of diabetic nephropathy (DN), which is one of the DM microvascular complications [3]. Studies have pointed out that inflammation might play an important role in DM and its vascular events [4]. The neutrophil-tolymphocyte (N/L) ratio was defined as a biomarker of inflammation [5]. However, the relationship between N/L ratio and cIMT and albuminuria in DM has not been fully investigated. The objective of the current study was to investigate the relation between cIMT (as a surrogate of macrovascular predictor) and albuminuria (as a surrogate of microvascular predictor) with N/L ratio in patients with type 2 DM.

Patients and methods Patients groups

A total of 240 patients with type 2 DM who were being followed up in the Internal Medicine Department of Assiut University Hospital from May 2017 to May 2018 were enrolled. Overall, 105 patients were excluded. Patients without background retinopathy, cIMT greater than 1 mm, estimated glomerular filtration rate (eGFR) less than 110 ml/min, and urinary albumin creatinine ratio greater than 30 were classified as diabetic control group (63 patients), whereas 62 patients with the previous characteristics and had normal renal US result, no pyuria, no

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.





Patients flow chart.

hematuria, normal C3 and C4, negative HIV, hepatitis B virus and hepatitis C virus serology, and normal plasma protein electrophoresis were classified as vascular complicated diabetic cases group (Fig. 1).

Ethical considerations

Written consents were obtained from all of the participants; illiterate participants gave their consent by fingerprints. The study was approved by the Ethical Committee of College of Medicine of Assiut University.

Demographic and clinical data

Patients' demographic data and medical history included age, sex, duration of diabetes, type of antidiabetic therapy, use of antihypertension medications, and smoking index (number of cigarette/number of years). BMI was calculated as the weight (kg) divided by the square of height (m²). Systolic blood pressure (SBP) and diastolic blood pressure of the patients were measured with a mercury sphygmomanometer after 15 min of recumbency.

Laboratory data

Venous blood samples were collected from our patients and analyzed in the Clinical Pathology Department Laboratory. Laboratory measurements, including serum levels of creatinine, blood urea nitrogen, lowdensity lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride, fasting blood glucose, HBA1c, and serum albumin were measured using standard kits. eGFR was calculated according to the Modification of Diet in Renal Disease formula. The complete blood count was measured using an automated complete blood cell counter (Cell Dyn Ruby; Abbott, USA), which simultaneously provided values for total white blood cell count, red blood count, hemoglobin, platelet count, absolute neutrophil count, and absolute lymphocyte

count. N/L ratio was calculated as a simple ratio of the absolute neutrophil count to the absolute lymphocyte count.

Ultrasonic data

The cIMT of both carotid arteries was measured by using HDI 5000 instrument (Philips Medical Systems, Bothell, Washington, USA) using linear probe, and the average of three results of each side was used. Diabetic patients were divided into two groups according to the cIMT values: diabetic control group with low cIMT (cIMT ≤ 1 mm) and vascular complicated diabetic cases group with high cIMT (cIMT >1 mm).

Fundoscopy

Retinopathy was tested by using the standard direct fundoscopic examination method.

Statistical analysis

The statistical analysis was performed using SPSS (version 19.0; SPSS Inc., Chicago, Illinois, USA). The Kolmogorov-Smirnov test was used to test normally. The continuous variables were presented as the means±SD, and categorical variables were reported as number and percentage. χ^2 test was used to compare between categorical variables, and continuous variables were compared using a t-test. analysis was used to identify Multivariate independent predictors of cIMT and albuminuria. A receiver operator characteristic curve analysis was performed to identify the sensitivity and specificity of N/L ratio cutoff values in prediction of microalbuminuria, macroalbuminuria, and cIMT. A P value less than 0.05 was considered statistically significant.

Results

Demographic and clinical characteristics

The study showed that vascular complicated diabetic cases had statistically significant higher duration of diabetes, percent of insulin use, percent of antihypertension medication use, and smoking index (Table 1).

Laboratory data

The study showed that vascular complicated diabetic cases had statistically significant higher levels of HBA1c, fasting blood glucose, LDL-C, triglyceride, serum creatinine, blood urea nitrogen, eGFR, and N/L ratio, with a statistically significant lower level of HDL-C (Table 1).

Multivariate linear regression analysis data

 R^2 of this regression models was 82.68%, which explains most of cIMT changes. The independent

Table 1	Study	population	characteristics'
---------	-------	------------	------------------

VariablesVC diabetic cases (n=62)Diabetic control (n=63)P valueAge (years) 59.57 ± 12.49 56.60 ± 11.65 0.187 Sex: female (%) 46.77 44.91 0.295 Duration of DM (years) 10.78 ± 4.18 7.83 ± 5.81 0.000 Insulin used (%) 55.53 33.87 0.000 Anti HTN (%) 75.48 55.95 0.000 Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 BMI (kg/m ²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum alburnin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.663 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 $1.73 m^2$) u u 68.38 ± 20.10 n u $a0$ $a0$ 68.38 ± 20.10 $a0$ $a.36\pm2.22$ 0.000 $a1.53\pm5.99$ 8.36 ± 2.22 0.000 Neutrophils (cell/ 68.38 ± 20.10 58.30 ± 11.63 0.000 mm ³) 1.53 ± 5.99 8.36 ± 2.22 0.000 N/L ratio $8.01\pm7.$	Variables VC diabetic Diabetic P						
Age (years) 59.57 ± 12.49 56.60 ± 11.65 0.187 Sex: female (%) 46.77 44.91 0.295 Duration of DM 10.78 ± 4.18 7.83 ± 5.81 0.000 (years)10.78±4.18 7.83 ± 5.81 0.000 Anti HTN (%) 75.48 55.95 0.000 Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 BMI (kg/m ²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.063 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 aGR <30 (mg/g)	variables						
Sex: female (%)46.7744.910.295Duration of DM (years)10.78 \pm 4.187.83 \pm 5.810.000Insulin used (%)55.5333.870.000Anti HTN (%)75.4855.950.000Smoking index746.46 \pm 65.43576.12 \pm 35.950.000BMI (kg/m ²)27.54 \pm 3.5626.27 \pm 7.030.198SBP (mmHg)128.34 \pm 14.43124.94 \pm 15.530.765DBP (mmhg)88.87 \pm 16.9486.53 \pm 13.490.876HBA1c (%)9.34 \pm 2.297.34 \pm 2.440.000FBG (mg/dl)128.56 \pm 12.36119.32 \pm 28.080.048LDL-c (mg/dl)136.19 \pm 56.89125.64 \pm 38.740.038HDL-c (mg/dl)34.36 \pm 56.8949.74 \pm 58.510.022Triglyceride (mg/dl)322.48 \pm 34.98287.40 \pm 25.460.000Serum albumin (g/l)37.37 \pm 5.5839.30 \pm 4.730.063Creatinine (µmol/l)23.15 \pm 10.606.71 \pm 3.250.000BUN (mmol/l)23.15 \pm 10.60145.65 \pm 22.340.000UACR <30 (mg/g)		· · · · ·	. ,				
Duration of DM (years) 10.78 ± 4.18 7.83 ± 5.81 0.000 Insulin used (%) 55.53 33.87 0.000 Anti HTN (%) 75.48 55.95 0.000 Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 BMI (kg/m ²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.663 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 eGFR (ml/min/ 89.45 ± 10.60 145.65 ± 22.34 0.000 $1.73 m^2$) $uACR < 30 (mg/g)$ $62 (100.0)$ $0 (00.0)$ $-$ > 300 $22 (35.48)$ $0 (0.0)$ $ >300$ $22 (35.48)$ $0 (0.0)$ $-$ HB (g/dl) 11.92 ± 1.83 12.42 ± 1.96 0.329 WBCs (cell/mm³) 11.53 ± 5.99 8.36 ± 2.22 0.000 Neutrophils (cell/ 68.38 ± 20.10 58.30 ± 11.63 0.000 mm³) 14.96 ± 9.27 31.81 ± 10.44 <td>0 0)</td> <td></td> <td></td> <td></td>	0 0)						
(years)Insulin used (%) 55.53 33.87 0.000 Anti HTN (%) 75.48 55.95 0.000 Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 BMI (kg/m ²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.063 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 145.65 ± 22.34 0.000 LVR <30 (mg/g)	()						
Insulin used (%)55.5333.870.000Anti HTN (%)75.4855.950.000Smoking index746.46 \pm 65.43576.12 \pm 35.950.000BMI (kg/m²)27.54 \pm 3.5626.27 \pm 7.030.198SBP (mmHg)128.34 \pm 14.43124.94 \pm 15.530.765DBP (mmhg)88.87 \pm 16.9486.53 \pm 13.490.876HBA1c (%)9.34 \pm 2.297.34 \pm 2.440.000FBG (mg/dl)128.56 \pm 12.36119.32 \pm 28.080.048LDL-c (mg/dl)136.19 \pm 56.89125.64 \pm 38.740.038HDL-c (mg/dl)34.36 \pm 56.8949.74 \pm 58.510.022Triglyceride (mg/dl)322.48 \pm 34.98287.40 \pm 25.460.000Serum albumin (g/l)37.37 \pm 5.5839.30 \pm 4.730.063Creatinine (µmol/l)23.15 \pm 10.606.71 \pm 3.250.000BUN (mmol/l)23.15 \pm 10.60145.65 \pm 22.340.000UACR <30 (mg/g)		10.78±4.18	7.83±5.81	0.000			
Anti HTN (%)75.4855.950.000Smoking index746.46 \pm 65.43576.12 \pm 35.950.000BMI (kg/m²)27.54 \pm 3.5626.27 \pm 7.030.198SBP (mmHg)128.34 \pm 14.43124.94 \pm 15.530.765DBP (mmhg)88.87 \pm 16.9486.53 \pm 13.490.876HBA1c (%)9.34 \pm 2.297.34 \pm 2.440.000FBG (mg/dl)128.56 \pm 12.36119.32 \pm 28.080.048LDL-c (mg/dl)136.19 \pm 56.89125.64 \pm 38.740.038HDL-c (mg/dl)34.36 \pm 56.8949.74 \pm 58.510.022Triglyceride (mg/dl)322.48 \pm 34.98287.40 \pm 25.460.000Serum albumin (g/l)37.37 \pm 5.5839.30 \pm 4.730.063Creatinine (µmol/l)23.15 \pm 10.606.71 \pm 3.250.000BUN (mmol/l)23.15 \pm 10.606.71 \pm 3.250.000UACR <30 (mg/g)	0 /		00.07				
Smoking index 746.46 ± 65.43 576.12 ± 35.95 0.000 BMI (kg/m²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.663 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 UACR <30 (mg/g)	()						
BMI (kg/m²) 27.54 ± 3.56 26.27 ± 7.03 0.198 SBP (mmHg) 128.34 ± 14.43 124.94 ± 15.53 0.765 DBP (mmhg) 88.87 ± 16.94 86.53 ± 13.49 0.876 HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.063 Creatinine (µmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 eGFR (ml/min/ 89.45 ± 10.60 145.65 ± 22.34 0.000 $1.73 m^2$) $uACR < 30$ (mg/g) 62 (100.0) 0 (00.0) $ >300$ 22 (35.48) 0 (0.0) $ >300$ 22 (35.48) 0 (0.0) $ HB$ (g/dl) 11.53 ± 5.99 8.36 ± 2.22 0.000 Neutrophils (cell/ mm³) 68.38 ± 20.10 58.30 ± 11.63 0.000 mm³) NL ratio 8.01 ± 7.62 2.10 ± 1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000	. ,						
$\begin{array}{llllllllllllllllllllllllllllllllllll$	0						
$\begin{array}{ccccc} & & & & & & & & & & & & & & & & &$							
HBA1c (%) 9.34 ± 2.29 7.34 ± 2.44 0.000 FBG (mg/dl) 128.56 ± 12.36 119.32 ± 28.08 0.048 LDL-c (mg/dl) 136.19 ± 56.89 125.64 ± 38.74 0.038 HDL-c (mg/dl) 34.36 ± 56.89 49.74 ± 58.51 0.022 Triglyceride (mg/dl) 322.48 ± 34.98 287.40 ± 25.46 0.000 Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.063 Creatinine (µmol/l) 367.98 ± 125.32 82.20 ± 18.42 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 eGFR (ml/min/ 89.45 ± 10.60 145.65 ± 22.34 0.000 1.73 m^2) u $acc (100.0)$ 0 $ 30-300$ 40 (64.51) 0 0 $ >300$ 22 (35.48) 0 0.00 $-$ HB (g/dl) 11.92 ± 1.83 12.42 ± 1.96 0.329 WBCs (cell/mm ³) 11.53 ± 5.99 8.36 ± 2.22 0.000 Neutrophils (cell/ 68.38 ± 20.10 58.30 ± 11.63 0.000 mm ³) N/L ratio 8.01 ± 7.62 2.10 ± 1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 $0(0.0.)$ 0.000	(0)						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	· •	88.87±16.94	86.53±13.49				
$ \begin{array}{c cccc} LDL-c (mg/dl) & 136.19\pm56.89 & 125.64\pm38.74 & 0.038 \\ HDL-c (mg/dl) & 34.36\pm56.89 & 49.74\pm58.51 & 0.022 \\ Triglyceride (mg/dl) & 322.48\pm34.98 & 287.40\pm25.46 & 0.000 \\ Serum albumin (g/l) & 37.37\pm5.58 & 39.30\pm4.73 & 0.063 \\ Creatinine (µmol/l) & 367.98\pm125.32 & 82.20\pm18.42 & 0.000 \\ BUN (mmol/l) & 23.15\pm10.60 & 6.71\pm3.25 & 0.000 \\ eGFR (ml/min/ & 89.45\pm10.60 & 145.65\pm22.34 & 0.000 \\ 1.73 m^2) & & & & & & & & & & & & & & & & & & &$	HBA1c (%)	9.34±2.29	7.34±2.44	0.000			
$\begin{array}{c cccc} \text{HDL-c (mg/dl)} & 34.36\pm56.89 & 49.74\pm58.51 & 0.022 \\ \text{Triglyceride (mg/dl)} & 322.48\pm34.98 & 287.40\pm25.46 & 0.000 \\ \text{Serum albumin (g/l)} & 37.37\pm5.58 & 39.30\pm4.73 & 0.063 \\ \text{Creatinine (µmol/l)} & 367.98\pm125.32 & 82.20\pm18.42 & 0.000 \\ \text{BUN (mmol/l)} & 23.15\pm10.60 & 6.71\pm3.25 & 0.000 \\ \text{eGFR (ml/min/} & 89.45\pm10.60 & 145.65\pm22.34 & 0.000 \\ 1.73 \text{m}^2) & & & & & & & & & \\ \text{uACR} < 30 (mg/g) & 62 (100.0) & 0 (00.0) & - \\ > 30-300 & 40 (64.51) & 0 (0.0) & - \\ > 300 & 22 (35.48) & 0 (0.0) & - \\ \text{HB (g/dl)} & 11.92\pm1.83 & 12.42\pm1.96 & 0.329 \\ \text{WBCs (cell/mm^3)} & 11.53\pm5.99 & 8.36\pm2.22 & 0.000 \\ \text{Neutrophils (cell/} & 68.38\pm20.10 & 58.30\pm11.63 & 0.000 \\ \text{mm^3)} \\ \text{Lymphocytes (cell/} & 14.96\pm9.27 & 31.81\pm10.44 & 0.000 \\ \text{mm^3)} \\ \text{N/L ratio} & 8.01\pm7.62 & 2.10\pm1.02 & 0.000 \\ \text{Retinopathy: yes (\%)} & 44 (70.96) & 0 (00.0) & 0.000 \end{array}$	FBG (mg/dl)	128.56±12.36	119.32±28.08	0.048			
$\begin{array}{cccc} \mbox{Triglyceride (mg/dl)} & 322.48 \pm 34.98 \\ \mbox{Serum albumin (g/l)} & 37.37 \pm 5.58 \\ \mbox{Serum albumin (g/l)} & 37.37 \pm 5.58 \\ \mbox{Creatinine (μmol/l$)} & 367.98 \pm 125.32 \\ \mbox{BUN (mmol/l$)} & 23.15 \pm 10.60 \\ \mbox{eGFR (ml/min/} & 89.45 \pm 10.60 \\ \mbox{1.73 m}^2\) & & & & & & & & \\ \mbox{uACR $<$30 (mg/g$)} & 62 (100.0) \\ \mbox{0.00} & 0 (00.0) \\ \mbox{-} \\ \mbox{300} & 40 (64.51) \\ \mbox{0.00} & 0 (00.0) \\ \mbox{-} \\ \mbox{300} & 22 (35.48) \\ \mbox{0.00} & 0 (00.0) \\ \mbox{-} \\ \mbox{HB (g/dl)} \\ \mbox{11.92 \pm 1.83} \\ \mbox{12.42 \pm 1.96} \\ \mbox{0.329} \\ \mbox{WBCs (cell/mm^3)} \\ \mbox{11.53 \pm 5.99} \\ \mbox{8.36 \pm 2.22} \\ \mbox{0.000} \\ \mbox{nm^3)} \\ \mbox{Lymphocytes (cell/} \\ \mbox{14.96 \pm 9.27} \\ \mbox{31.81 \pm 10.44} \\ \mbox{0.000} \\ \mbox{mm^3)} \\ \mbox{N/L ratio} \\ \mbox{8.01 \pm 7.62} \\ \mbox{2.10 \pm 1.02} \\ \mbox{0.000} \\ 0.00$	LDL-c (mg/dl)	136.19±56.89	125.64±38.74	0.038			
Serum albumin (g/l) 37.37 ± 5.58 39.30 ± 4.73 0.063 Creatinine (µmol/l) 367.98 ± 125.32 82.20 ± 18.42 0.000 BUN (mmol/l) 23.15 ± 10.60 6.71 ± 3.25 0.000 eGFR (ml/min/ 89.45 ± 10.60 145.65 ± 22.34 0.000 $1.73 m^2$) $uACR < 30$ (mg/g) 62 (100.0) 0 (00.0) $ 30-300$ 40 (64.51) 0 (0.0) $ >300$ 22 (35.48) 0 (0.0) $-$ HB (g/dl) 11.92 ± 1.83 12.42 ± 1.96 0.329 WBCs (cell/mm³) 11.53 ± 5.99 8.36 ± 2.22 0.000 Neutrophils (cell/ 68.38 ± 20.10 58.30 ± 11.63 0.000 mm³) N/L ratio 8.01 ± 7.62 2.10 ± 1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000	HDL-c (mg/dl)	34.36±56.89	49.74±58.51	0.022			
$\begin{array}{c cccc} Creatinine (\mumol/l) & 367.98 \pm 125.32 & 82.20 \pm 18.42 & 0.000 \\ BUN (mmol/l) & 23.15 \pm 10.60 & 6.71 \pm 3.25 & 0.000 \\ eGFR (ml/min/ & 89.45 \pm 10.60 & 145.65 \pm 22.34 & 0.000 \\ 1.73 \mathrm{m}^2) & & & & & & & & & & & & & & & & & & &$	Triglyceride (mg/dl)	322.48±34.98	287.40±25.46	0.000			
$\begin{array}{c ccccc} \text{BUN (mmol)} & 23.15\pm10.60 & 6.71\pm3.25 & 0.000 \\ \text{eGFR (ml/min/} & 89.45\pm10.60 & 145.65\pm22.34 & 0.000 \\ 1.73 \text{m}^2) & & & & & & & \\ \text{uACR} < 30 (mg/g) & 62 (100.0) & 0 (00.0) & - \\ 30-300 & 40 (64.51) & 0 (0.0) & - \\ >300 & 22 (35.48) & 0 (0.0) & - \\ \text{HB (g/dl)} & 11.92\pm1.83 & 12.42\pm1.96 & 0.329 \\ \text{WBCs (cell/mm^3)} & 11.53\pm5.99 & 8.36\pm2.22 & 0.000 \\ \text{Neutrophils (cell/} & 68.38\pm20.10 & 58.30\pm11.63 & 0.000 \\ \text{mm}^3) & & & \\ \text{Lymphocytes (cell/} & 14.96\pm9.27 & 31.81\pm10.44 & 0.000 \\ \text{mm}^3) \\ \text{N/L ratio} & 8.01\pm7.62 & 2.10\pm1.02 & 0.000 \\ \text{Retinopathy: yes (\%)} & 44 (70.96) & 0 (00.0) & 0.000 \end{array}$	Serum albumin (g/l)	37.37±5.58	39.30±4.73	0.063			
$\begin{array}{c} \mbox{eGFR} (ml/mi/ \\ 1.73 \mbox{ m}^2) \\ \mbox{uACR} < 30 \mbox{ (mg/g)} \\ 62 \mbox{ (100.0)} \\ 0 \mbox{ (00.0)} \\ - \\ 30-300 \\ 22 \mbox{ (35.48)} \\ 0 \mbox{ (0.0)} \\ - \\ 300 \\ 22 \mbox{ (35.48)} \\ 0 \mbox{ (0.0)} \\ - \\ HB \mbox{ (g/dl)} \\ 11.92 \pm 1.83 \\ 12.42 \pm 1.96 \\ 0.329 \\ WBCs \mbox{ (cell/mm^3)} \\ 11.53 \pm 5.99 \\ 8.36 \pm 2.22 \\ 0.000 \\ Neutrophils \mbox{ (cell/} \\ 68.38 \pm 20.10 \\ mm^3) \\ Lymphocytes \mbox{ (cell/} \\ 14.96 \pm 9.27 \\ mm^3) \\ N/L \mbox{ ratio} \\ 8.01 \pm 7.62 \\ 2.10 \pm 1.02 \\ 0.000 \\ Retinopathy: \mbox{ yes} \mbox{ (\%)} \\ 44 \mbox{ (70.96)} \\ 0 \mbox{ (00.0)} \\ 0.000 \end{array}$	Creatinine (µmol/l)	367.98±125.32	82.20±18.42	0.000			
$\begin{array}{c ccccc} 1.73 \ \text{m}^2 \\ \text{uACR} < 30 \ (\text{mg/g}) & 62 \ (100.0) & 0 \ (00.0) & - \\ 30-300 & 40 \ (64.51) & 0 \ (0.0) & - \\ > 300 & 22 \ (35.48) & 0 \ (0.0) & - \\ \text{HB} \ (\text{g/dl}) & 11.92 \pm 1.83 & 12.42 \pm 1.96 & 0.329 \\ \text{WBCs} \ (\text{cell/mm}^3) & 11.53 \pm 5.99 & 8.36 \pm 2.22 & 0.000 \\ \text{Neutrophils} \ (\text{cell/} & 68.38 \pm 20.10 & 58.30 \pm 11.63 & 0.000 \\ \text{mm}^3 \\ \text{Lymphocytes} \ (\text{cell/} & 14.96 \pm 9.27 & 31.81 \pm 10.44 & 0.000 \\ \text{mm}^3 \\ \text{N/L ratio} & 8.01 \pm 7.62 & 2.10 \pm 1.02 & 0.000 \\ \text{Retinopathy: yes} \ (\%) & 44 \ (70.96) & 0 \ (00.0) & 0.000 \end{array}$	BUN (mmol/l)	23.15±10.60	6.71±3.25	0.000			
$\begin{array}{cccccccc} 30-300 & 40 \ (64.51) & 0 \ (0.0) & -\\ >300 & 22 \ (35.48) & 0 \ (0.0) & -\\ HB \ (g/dl) & 11.92\pm 1.83 & 12.42\pm 1.96 & 0.329 \\ WBCs \ (cell/mm^3) & 11.53\pm 5.99 & 8.36\pm 2.22 & 0.000 \\ Neutrophils \ (cell/ & 68.38\pm 20.10 & 58.30\pm 11.63 & 0.000 \\ mm^3) & & & & & & \\ Lymphocytes \ (cell/ & 14.96\pm 9.27 & 31.81\pm 10.44 & 0.000 \\ mm^3) & & & & & & \\ N/L \ ratio & 8.01\pm 7.62 & 2.10\pm 1.02 & 0.000 \\ Retinopathy: \ yes \ (\%) & 44 \ (70.96) & 0 \ (00.0) & 0.000 \end{array}$		89.45±10.60	145.65±22.34	0.000			
$\begin{array}{c ccccc} >300 & 22 & (35.48) & 0 & (0.0) & - \\ HB & (g/dl) & 11.92 \pm 1.83 & 12.42 \pm 1.96 & 0.329 \\ WBCs & (cell/mm^3) & 11.53 \pm 5.99 & 8.36 \pm 2.22 & 0.000 \\ Neutrophils & (cell/ & 68.38 \pm 20.10 & 58.30 \pm 11.63 & 0.000 \\ mm^3) & & & & \\ Lymphocytes & (cell/ & 14.96 \pm 9.27 & 31.81 \pm 10.44 & 0.000 \\ mm^3) & & & & \\ N/L & ratio & 8.01 \pm 7.62 & 2.10 \pm 1.02 & 0.000 \\ Retinopathy: & yes & (\%) & 44 & (70.96) & 0 & (00.0) & 0.000 \\ \end{array}$	uACR <30 (mg/g)	62 (100.0)	0 (00.0)	_			
$\begin{array}{c cccc} HB \ (g/dl) & 11.92 \pm 1.83 & 12.42 \pm 1.96 & 0.329 \\ WBCs \ (cell/mm^3) & 11.53 \pm 5.99 & 8.36 \pm 2.22 & 0.000 \\ Neutrophils \ (cell/ & 68.38 \pm 20.10 & 58.30 \pm 11.63 & 0.000 \\ mm^3) & & & & & \\ Lymphocytes \ (cell/ & 14.96 \pm 9.27 & 31.81 \pm 10.44 & 0.000 \\ mm^3) & & & & & \\ N/L \ ratio & 8.01 \pm 7.62 & 2.10 \pm 1.02 & 0.000 \\ Retinopathy: \ yes \ (\%) & 44 \ (70.96) & 0 \ (00.0) & 0.000 \end{array}$	30–300	40 (64.51)	0 (0.0)	_			
WBCs (cell/mm ³) 11.53±5.99 8.36±2.22 0.000 Neutrophils (cell/ 68.38±20.10 58.30±11.63 0.000 mm ³) Lymphocytes (cell/ 14.96±9.27 31.81±10.44 0.000 mm ³) N/L ratio 8.01±7.62 2.10±1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000	>300	22 (35.48)	0 (0.0)	_			
Neutrophils (cell/ mm ³) 68.38±20.10 58.30±11.63 0.000 Lymphocytes (cell/ mm ³) 14.96±9.27 31.81±10.44 0.000 N/L ratio 8.01±7.62 2.10±1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000	HB (g/dl)	11.92±1.83	12.42±1.96	0.329			
mm ³) Lymphocytes (cell/ 14.96±9.27 31.81±10.44 0.000 mm ³) N/L ratio 8.01±7.62 2.10±1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000	WBCs (cell/mm ³)	11.53±5.99	8.36±2.22	0.000			
mm ³) N/L ratio 8.01±7.62 2.10±1.02 0.000 Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000		68.38±20.10	58.30±11.63	0.000			
Retinopathy: yes (%) 44 (70.96) 0 (00.0) 0.000		14.96±9.27	31.81±10.44	0.000			
	N/L ratio	8.01±7.62	2.10±1.02	0.000			
cIMT (mm) 1.2±0.01 0.7±0.02 0.007	Retinopathy: yes (%)	44 (70.96)	0 (00.0)	0.000			
	cIMT (mm)	1.2±0.01	0.7±0.02	0.007			

Values are expressed as means±SD and number (%). BUN, blood urea nitrogen; cIMT, carotid intima-medial thickness; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HB A1c, hemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; N/L ratio, neutrophil-tolymphocyte ratio; SBP, systolic blood pressure; uACR, urinary albumin-creatinine ratio; VC, vascular complicated; WBCs; white blood cells.

predictors of cIMT include age, male sex, smoking, duration of diabetes, LDL, HBA1c, and N/L ratio (Table 2).

 R^2 of this regression models was 80.67%. The independent predictors of albuminuria include duration of diabetes, HBA1c, SBP, BMI, eGFR, and N/L ratio (Table 3).

Receiver operator characteristic curve analysis data

Receiver operator characteristic curve analysis of N/L ratio, as a diagnostic marker for cIMT greater than 1 mm, at a cutoff value of 2.7 showed a sensitivity and specificity of 100 and 55.45%, respectively, with area under the curve (AUC) of 0.748 (Table 4 and Fig. 2).

 Table 2 Multivariate analysis of independent predictors of carotid artery intima-media thickness

Model	В	t	P value	95% confidence interval
Age (years)	0.355	7.450	0.000	0.177 to 0.533
Male gender	2.364	5.640	0.000	4.408 to 0.319
Smoking index	1.016	3.452	0.043	0.202 to 1.829
Duration of DM (years)	0.391	4.639	0.022	0.497 to 0.286
eGFR (ml/min)	-0.001	1.387	0.052	-0.005 to 0.003
LDL (mg/dl)	0.677	4.927	0.027	1.287 to 0.068
HDL (mg/dl)	-0.002	0.761	0.283	-0.005 to 0.001
Triglyceride (mg/ dl)	0.010	0.239	0.762	-0.007 to 0.027
uACR	-0.001	0.268	0.065	-0.002 to 0.000
HBA1c (%)	0.018	5.219	0.027	0.013 to 0.023
N/L ratio	0.003	8.325	0.000	0.001 to 0.006

Dependent variable: cIMT (carotid intima-medial thickness). DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; N/L ratio, neutrophil/lymphocyte ratio; uACR, urinary albumin-creatinine ratio.

Table 3 Multivariate analysis of independent predictors of albuminuria

Model	β	t	P value	95% confidence interval
Duration of DM (years)	0.090	5.428	0.000	0.043 to 0.137
HBA1c (%)	0.133	4.848	0.027	0.008 to 0.259
SBP (mmHg)	0.855	3.922	0.032	0.320 to 1.390
BMI (kg/m ²)	0.497	3.362	0.022	0.486 to 0.508
eGFR (ml/min)	-0.064	5.427	0.006	-0.102 to -0.027
Serum albumin (g/ I)	-0.946	0.765	0.125	-2.338 to 0.445
N/L ratio	0.110	3.638	0.006	0.195 to 0.026

Dependent variable: albuminuria. DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; N/L ratio, neutrophillymphocyte ratio; SBP, systolic blood pressure.

N/L ratio at a cut-off value of 3.7 showed sensitivity and specificity of 62.12 and 96.30%, respectively, with AUC of 0.863, when used as a diagnostic marker for uACR greater than 30 (Table 5 and Fig. 3).

N/L ratio at a cutoff value of 7 had sensitivity and specificity of 75.00 and 95.00%, respectively, and AUC of 0.830, when used as a diagnostic marker of macroalbuminuria (uACR >300) (Table 6 and Fig. 4).

Discussion

Use of vascular imaging to identify and quantify the presence of subclinical atherosclerosis is recommended to refine cardiovascular (CV) risk assessment [6]. Measuring cIMT with ultrasound is a noninvasive, sensitive, and reproducible technique for quantifying atherosclerotic burden [7]. Type 2 DM has twofold to fivefold increased risk of atherosclerosis which

Table 4 Receiver operator characteristic analysis for neutrophil-to-lymphocyte ratio as a predictor of carotid artery intima-media thickness


Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy	AUC
>2.7	100.00	55.45	16.9	100.0	59.2	0.748
AUC, area under the curve; PPV, positive predictive value; NPV,						

negative predictive value.

predispose to its macrovascular complications, including ischemic heart disease, stroke, and peripheral artery disease [8]. A high N/L ratio is a predictive biomarker of progression of atherosclerosis [9]. The current study showed that N/L ratio is one of the independent predictor of cIMT in patients with type 2 DM in addition to other conventional CV risk factors, including age, male sex, smoking, duration of diabetes, LDL, and HBA1c. These results are consistent with previous studies that showed that N/ L ratio was an independent predictor for high cIMT in patients with DM [10] as well as a predictive biomarker of progression of atherosclerosis [9]. Other studies have supported that conventional risk factors such as age, BMI, male sex, systolic BP, higher level of LDL-C, smoking [11,12,13], diabetic state [14], and uACR [15,16] were associated with increased cIMT.


However, the exact mechanisms of high N/L ratio being related with increased cIMT in diabetes patients are as yet unknown. One mechanism is that neutrophil infiltration of the arterial wall plays an important role in the progression of atherosclerosis and makes plaques more vulnerable through the release of proteolytic enzymes [17]. Another possible mechanism is that N/L ratio can reflect an autonomic imbalance of the vascular bed. Sympathetic nerves stimulate granulocytes, whereas parasympathetic nerves stimulate lymphocytes [18]. Therefore, a higher level of N/L ratio may indicate a high sympathetic-toparasympathetic activity ratio. Sympathetic tone increases oxygen consumption and increases production of proinflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor- α [19]. These cytokines stimulate smooth muscle and interstitial cell proliferation, which could accelerate atherosclerosis development [20].

The microvascular complications of DM classically include retinopathy, neuropathy, and nephropathy. DN leads to significant problems in 25–40% of diabetic patients and is the major cause of endstage renal failure [21]. Albuminuria is the basic finding of renal damage and is linked to the progression of kidney diseases [22]. Albuminuria serves as a biochemical biomarker for DN development and progression [23].



Receiver operator characteristic curve for neutrophil-to-lymphocyte ratio as a predictor of carotid artery intima-media thickness.

Fig. 3



Receiver operator characteristic curve for neutrophil-to-lymphocyte ratio as a predictor of albuminuria (albumin creatinine ratio > 30).

Table 5 Receiver operator characteristic analysis forneutrophil-to-lymphocyte ratio as a predictor of albuminuria(albumin creatinine ratio >30)

Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy	AUC
>3.7	62.12	96.30	95.3	67.5	77.5	0.863

AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

A growing evidence has emphasized the critical role of inflammation in the pathogenesis of DN, which results in elevated circulating levels of pro-inflammatory cytokines [24] such as tumor necrosis factor- α and IL-1 β [25], IL-18, interferon gamma induced protein


Table 6 Receiver operator characteristic analysis for neutrophil-to-lymphocyte ratio as a predictor of macroalbuminuria (albumin creatinine ratio > 300)

Cut-off	Sensitivity	Specificity	PPV	NPV	Accuracy	AUC
>7	75.00	95.00	75.0	95.0	91.7	0.830

AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

(IP-10), monocyte chemo-attractant protein 1 (MCP-1) [26], granulocyte colony-stimulating factor (G-CSF) [27], eotaxins (regulated on activation, normal T cell expressed and secreted), RANTES or CCL-5, and orosomucoid [28]. These cytokines change





Receiver operator characteristic curve for neutrophil-to-lymphocyte ratio as a predictor of macroalbuminuria (albumin creatinine ratio > 300).

leukocyte levels. However; the biological mechanisms by which leukocytes and their subtypes play a role in mediating increased protein and albumin excretion and retinal injury are not fully known. The current study showed that N/L ratio is independently associated with albuminuria in patients with type 2 DM in addition to duration of diabetes, HBA1c, SBP, BMI, and eGFR.

Previous studies have shown that N/L ratio is independently associated with proteinuria in patients with type 2 DM [29,30,31], even after adjustment for other known endothelial and CV risk factors (age, hypertension, dyslipidemia, diabetes, or altered GFR) [32]. N/L ratio has been associated with proteinuria in older type 2 diabetic patients [33,34], and in newly diagnosed patients with type 2 DM [30,35,34] mentioned a negative correlation between granulocytic count and GFR.

Moreover, previous studies have shown that proteinuria is significantly correlated with total leukocytes, neutrophil, and monocyte counts [29] and N/L ratio [36] in patients with CKD regardless of the etiology. Previous studies also have mentioned that HBA1c [37,31], BMI [38], and BP [39] were independent factors of albuminuria. However, the relation between eGFR and proteinuria is not usually predictable and varies according to the presence and severity of proteinuria [40].

Conclusion

The current study showed that N/L ratio is an independent predictor of cIMT in patients with type

2 DM in addition to other conventional CV risk factors. Moreover, N/L ratio is an independent predictor of albuminuria in type 2 diabetic patients in addition to duration of diabetes, HBA1c, SBP, BMI, and eGFR.

Study limitations and recommendations

The main limitation was the limited study size. Future studies are required to clarify these relationships with a larger study sample. Ours was a monoethnic cross-sectional study, and we suggest a multiethnic prospective study to be carried out to identify clinical outcome. We recommend the use of N/L ratio as a cost-effective and readily accessible novel biomarker for macrovascular and microvascular complications of type 2 DM.

Acknowledgements

Authors would like to deeply thank workers and nursing stuff of Internal Medicine Department and Clinical Pathology Department in Assiut University Hospitals for their generous help and support in this study.

Muhammed H. Al-Maghraby was involved in design, definition of intellectual content, and manuscript review; Mohamed Z. Abdelrhman was involved in interpretation of laboratory results and manuscript review; Dr Walaa H. Mohammad was involved in literature search, clinical and experimental studies, data analysis, and manuscript editing; Dr Ahmad B.E. Ahmad was involved in performing echocardiography, statistical analysis, and manuscript editing; Dr Sanaa Ezzate was involved in literature search, data acquisition, and statistical analysis. Financial support and sponsorship Nil.

Conflicts of Interest

There are no conflicts of interest.

References

- 1 Wild S, Roglic G, Green A, Sicree King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047–1053.
- 2 Taniwaki H, Kawagishi T, Emoto M, Shoji T, Kanda H, Maekawa K, et al. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. Diabetes Care 1999; 22:1851–1857.
- 3 Uwaezuoke S. The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renov Dis. 2017; 10:221–231.
- 4 Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet Lond Engl 1999; 353:1649–1652.
- 5 Yuksel M, Yildiz A, Oylumlu M, Turkcu FM, Bilik MZ, Ekinci A, et al. Novel markers of endothelial dysfunction and inflammation in Behçet's disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clin Rheumatol 2016; 35:701–708.
- 6 Taylor AJ, Merz CNB, Udelson JE. 34th Bethesda Conference: executive summary – can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? J Am Coll Cardiol 2003; 41:1860–1862.
- 7 Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21:93–111.
- 8 Preis SR, Hwang S-J., Coady S, Pencina MJ, D'Agostino RB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119:1728–35.
- 9 Kalay N, Dogdu O, Koc F, Yarlıoglues M, Ardic I, Akpek M, et al. Hematologic parameters and angiographic progression of coronary atherosclerosis. Angiology 2012; 63:213–217.
- 10 Li X, Shen J, Lu Z, Chen M, Fang X, Wang G. High neutrophil-tolymphocyte ratio is associated with increased carotid artery intima-media thickness in type 2 diabetes. J Diabetes Investig. 2017; 8:101–107.
- 11 Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intimamedia thickness in adulthood: the cardiovascular risk in young finns study. JAMA 2003; 290:2277.
- 12 Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke 1997; 28:518–525.
- 13 Oren A, Vos LE, Uiterwaal CSPM, Grobbee DE, Bots ML. Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the atherosclerosis risk in young adults (ARYA) study. Arch Intern Med 2003; 163:1787.
- 14 Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 2006; 23:609–616.
- 15 Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and Carotid Artery Intima-Media Thickness in Nondiabetic and NIDDM Subjects: The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28:1710–1716.
- 16 Dehdashti Shahrokh H, Zakerkish M, Jenabi A, Hanafi MG, Rahim F, Rezazadeh A, et al. Association of microalburniuria and estimated glomerular filtration rate with carotid intima-media thickness in patients with type 2 diabetes mellitus. Jentashapir J Health Res. 2015; 6:2.
- 17 Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Direct viewing of atherosclerosis in vivo: plaque invasion by leukocytes is initiated by the endothelial selectins. FASEB J Off Publ Fed Am Soc Exp Biol 2001; 15:1149–1157.

- 18 Abo T, Kawamura T. Immunomodulation by the autonomic nervous system: therapeutic approach for cancer, collagen diseases, and inflammatory bowel diseases. Ther Apher Off J Int Soc Apher Jpn Soc Apher 2002; 6:348–357.
- 19 Tracey KJ. The inflammatory reflex. Nature 2002; 420:853-859.
- 20 Bhagat K, Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Curr Opin Nephrol Hypertens. 1999; 8:89–96.
- 21 Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis Off J Natl Kidney Found 1999; 34:795–808.
- 22 Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448–1456.
- **23** Sn U. Prevention of diabetic nephropathy in children and adolescents: how effective are the current strategies? Int J Diabetol Vasc Dis Res 2015; 1:1–5.
- 24 Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013; 114:525–531.
- 25 Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012; 30:49–59.
- 26 Kajitani N, Shikata K, Nakamura A, Nakatou T, Hiramatsu M, Makino H. Microinflammation is a common risk factor for progression of nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 88:171–176.
- 27 Perlman AS, Chevalier JM, Wilkinson P, Liu H, Parker T, Levine DM, et al. Serum inflammatory and immune mediators are elevated in early stage diabetic nephropathy. Ann Clin Lab Sci 2015; 45:256–263.
- 28 Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, Lai V, et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 2013; 56:1166–1173.
- 29 Huang W, Huang J, Liu Q, Lin F, He Z, Zeng Z, et al. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy. Clin Endocrinol (Oxf) 2015; 82:229–233.
- 30 Afsar B. The relationship between neutrophil lymphocyte ratio with urinary protein albumin excretion in newly diagnosed patients with type 2 diabetes. Am J Med Sci 2014; 347:217–220.
- 31 Akbas EM, Demirtas L, Ozcicek A, Timuroglu A, Bakirci EM, Hamur H, et al. Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic nephropathy. Int J Clin Exp Med 2014; 7:1794–1801.
- 32 Martínez-Urbistondo D, Beltrán A, Beloqui O, Huerta A. The neutrophil-tolymphocyte ratio as a marker of systemic endothelial dysfunction in asymptomatic subjects. Nefrol Publicacion Soc Espanola Nefrol 2016; 36:397–403.
- 33 Binnetoğlu E, Şengül E, Halhallı G, Dindar S, Şen H. Is neutrophil lymphocyte ratio an indicator for proteinuria in chronic kidney disease? Neutrophil lymphocyte ratio associated with proteinuria. J Clin Lab Anal 2014; 28:487–492.
- 34 Kahraman C, Kahraman NK, Aras B, Coşgun S, Gülcan E. The relationship between neutrophil-to-lymphocyte ratio and albuminuria in type 2 diabetic patients: a pilot study. Arch Med Sci 2016; 3:571–575.
- 35 Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol JASN 2005; 16:2431–2438.
- 36 Binnetoğlu E, Şengül E, Halhallı G, Dindar S, Şen H. Is neutrophil lymphocyte ratio an indicator for proteinuria in chronic kidney disease? Neutrophil lymphocyte ratio associated with proteinuria. J Clin Lab Anal. 2014; 28:487–492.
- 37 Watts GF, Powrie JK, O'Brien SF, Shaw KM. Apolipoprotein B independently predicts progression of very—low-level albuminuria in insulin-dependent diabetes mellitus. Metabolism 1996; 45:1101–1107.
- 38 Mohammedi K, Chalmers J, Herrington W, Li Q, Mancia G, Marre M, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes 2018; 8:7.
- 39 Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis. 2003; 41:588–595.
- **40** Turin TC, James M, Ravani P, Tonelli M, Manns BJ, Quinn R, *et al.* Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol 2013; 24:1661–1667.